Literature DB >> 19562250

Mortality rate of patients with asymptomatic primary biliary cirrhosis diagnosed at age 55 years or older is similar to that of the general population.

Junichi Kubota1, Fusao Ikeda, Ryo Terada, Haruhiko Kobashi, Shin-ichi Fujioka, Ryoichi Okamoto, Shinsuke Baba, Youichi Morimoto, Masaharu Ando, Yasuhiro Makino, Hideaki Taniguchi, Tetsuya Yasunaka, Yasuhiro Miyake, Yoshiaki Iwasaki, Kazuhide Yamamoto.   

Abstract

PURPOSE: Recent routine testing for liver function and anti-mitochondrial antibodies has increased the number of newly diagnosed patients with primary biliary cirrhosis (PBC). This study investigated the prognosis of asymptomatic PBC patients, focusing on age difference, to clarify its effect on the prognosis of PBC patients.
METHODS: The study was a systematic cohort analysis of 308 consecutive patients diagnosed with asymptomatic PBC. We compared prognosis between the elderly (55 years or older at the time of diagnosis) and the young patients (<55 years). The mortality rate of the patients was also compared with that of an age- and gender-matched general population.
RESULTS: The elderly patients showed a higher aspartate aminotransferase-to-platelet ratio, and lower alanine aminotransferase level than the young patients (P < 0.01 and P = 0.03, respectively). The two groups showed similar values for alkaline phosphatase and immunoglobulin M. Death in the young patients was more likely to be due to liver failure (71%), while the elderly were likely to die from other causes before the occurrence of liver failure (88%; P < 0.01), especially from malignancies (35%). The mortality rate of the elderly patients was not different from that of the age- and gender-matched general population (standardized mortality ratio, 1.1; 95% confidence interval, 0.6-1.7), although this rate was significantly higher than that of the young patients (P = 0.044).
CONCLUSIONS: PBC often presents as more advanced disease in elderly patients than in the young. However, the mortality rate of the elderly patients is not different from that of an age- and gender-matched general population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19562250     DOI: 10.1007/s00535-009-0090-2

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  32 in total

1.  The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis.

Authors:  C Corpechot; F Carrat; A M Bonnand; R E Poupon; R Poupon
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

2.  Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis.

Authors:  Renée Eugénie Poupon; Keith D Lindor; Albert Parés; Olivier Chazouillères; Raoul Poupon; E Jenny Heathcote
Journal:  J Hepatol       Date:  2003-07       Impact factor: 25.083

3.  Primary billiary cirrhosis (chronic intrahepatic obstructive jaundice).

Authors:  S SHERLOCK
Journal:  Gastroenterology       Date:  1959-11       Impact factor: 22.682

4.  Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort.

Authors:  M I Prince; A Chetwynd; W L Craig; J V Metcalf; O F W James
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

5.  Primary biliary cirrhosis.

Authors:  E H AHRENS; M A PAYNE; H G KUNKEL; W J EISENMENGER; S H BLONDHEIM
Journal:  Medicine (Baltimore)       Date:  1950-12       Impact factor: 1.889

Review 6.  Primary biliary cirrhosis.

Authors:  M M Kaplan
Journal:  N Engl J Med       Date:  1996-11-21       Impact factor: 91.245

7.  Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis.

Authors:  J Goulis; G Leandro; A K Burroughs
Journal:  Lancet       Date:  1999-09-25       Impact factor: 79.321

8.  Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines.

Authors:  E J Heathcote
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

9.  Epidemiology and natural history of primary biliary cirrhosis in a US community.

Authors:  W R Kim; K D Lindor; G R Locke; T M Therneau; H A Homburger; K P Batts; B P Yawn; J L Petz; L J Melton; E R Dickson
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

10.  Primary biliary cirrhosis: survival of a cohort followed for 10 years.

Authors:  P Uddenfeldt; A Danielsson
Journal:  J Intern Med       Date:  2000-10       Impact factor: 8.989

View more
  4 in total

1.  Laparoscopic findings of reddish markings predict hepatocellular carcinoma in patients with hepatitis B virus-related liver disease.

Authors:  Bon Shoji; Fusao Ikeda; Shin-ichi Fujioka; Haruhiko Kobashi; Tetsuya Yasunaka; Yasuhiro Miyake; Hidenori Shiraha; Akinobu Takaki; Kazuhiro Nouso; Yoshiaki Iwasaki; Kazuhide Yamamoto
Journal:  J Gastroenterol       Date:  2010-06-12       Impact factor: 7.527

2.  Extrahepatic malignancies in primary biliary cirrhosis: a comparative study at two European centers.

Authors:  Annarosa Floreani; Alice Spinazzè; Llorenc Caballeria; Ana Reig; Nora Cazzagon; Irene Franceschet; Alessandra Buja; Patrizia Furlan; Kenichi Harada; Patrick Sc Leung; M Eric Gershwin; Albert Pares
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 3.  Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists.

Authors:  Palak J Trivedi; Christophe Corpechot; Albert Pares; Gideon M Hirschfield
Journal:  Hepatology       Date:  2015-11-26       Impact factor: 17.425

4.  APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.

Authors:  Hong You; Xiong Ma; Cumali Efe; Guiqiang Wang; Sook-Hyang Jeong; Kazumichi Abe; Weijia Duan; Sha Chen; Yuanyuan Kong; Dong Zhang; Lai Wei; Fu-Sheng Wang; Han-Chieh Lin; Jin Mo Yang; Tawesak Tanwandee; Rino A Gani; Diana A Payawal; Barjesh C Sharma; Jinlin Hou; Osamu Yokosuka; A Kadir Dokmeci; Darrell Crawford; Jia-Horng Kao; Teerha Piratvisuth; Dong Jin Suh; Laurentius A Lesmana; Jose Sollano; George Lau; Shiv K Sarin; Masao Omata; Atsushi Tanaka; Jidong Jia
Journal:  Hepatol Int       Date:  2022-02-04       Impact factor: 6.047

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.